Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Monte Rosa Therapeutics, Inc. - Common Stock (NQ:GLUE)

5.545 +0.285 (+5.42%)
Streaming Delayed Price Updated: 1:30 PM EDT, Jul 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 138,270
Open 5.320
Bid (Size) 5.540 (2)
Ask (Size) 5.550 (3)
Prev. Close 5.260
Today's Range 5.305 - 5.595
52wk Range 3.500 - 12.40
Shares Outstanding 49,383,711
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-22.0%
-22.0%
1 Month
+22.9%
+22.9%
3 Month
+15.8%
+15.8%
6 Month
-4.7%
-4.7%
1 Year
+21.3%
+21.3%

More News

Read More
Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders
Via Benzinga
Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For March 20, 2025
Via Benzinga
Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Via Benzinga
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments”
Via AB Newswire
Topics Artificial Intelligence

Frequently Asked Questions

Is Monte Rosa Therapeutics, Inc. - Common Stock publicly traded?
Yes, Monte Rosa Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Monte Rosa Therapeutics, Inc. - Common Stock trade on?
Monte Rosa Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Monte Rosa Therapeutics, Inc. - Common Stock?
The ticker symbol for Monte Rosa Therapeutics, Inc. - Common Stock is GLUE on the Nasdaq Stock Market
What is the current price of Monte Rosa Therapeutics, Inc. - Common Stock?
The current price of Monte Rosa Therapeutics, Inc. - Common Stock is 5.545
When was Monte Rosa Therapeutics, Inc. - Common Stock last traded?
The last trade of Monte Rosa Therapeutics, Inc. - Common Stock was at 07/30/25 01:30 PM ET
What is the market capitalization of Monte Rosa Therapeutics, Inc. - Common Stock?
The market capitalization of Monte Rosa Therapeutics, Inc. - Common Stock is 273.83M
How many shares of Monte Rosa Therapeutics, Inc. - Common Stock are outstanding?
Monte Rosa Therapeutics, Inc. - Common Stock has 274M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.